174 related articles for article (PubMed ID: 31972009)
1. Assessment of ST2 for risk of death following graft-versus-host disease in pediatric and adult age groups.
Rowan CM; Pike F; Cooke KR; Krance R; Carpenter PA; Duncan C; Jacobsohn DA; Bollard CM; Cruz CRY; Malatpure A; Farag SS; Renbarger J; Liu H; Bakoyannis G; Hanash S; Paczesny S
Blood; 2020 Apr; 135(17):1428-1437. PubMed ID: 31972009
[TBL] [Abstract][Full Text] [Related]
2. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
3. An early-biomarker algorithm predicts lethal graft-versus-host disease and survival.
Hartwell MJ; Özbek U; Holler E; Renteria AS; Major-Monfried H; Reddy P; Aziz M; Hogan WJ; Ayuk F; Efebera YA; Hexner EO; Bunworasate U; Qayed M; Ordemann R; Wölfl M; Mielke S; Pawarode A; Chen YB; Devine S; Harris AC; Jagasia M; Kitko CL; Litzow MR; Kröger N; Locatelli F; Morales G; Nakamura R; Reshef R; Rösler W; Weber D; Wudhikarn K; Yanik GA; Levine JE; Ferrara JL
JCI Insight; 2017 Feb; 2(3):e89798. PubMed ID: 28194439
[No Abstract] [Full Text] [Related]
4. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
[TBL] [Abstract][Full Text] [Related]
5. ST2 and REG3α as Predictive Biomarkers After Haploidentical Stem Cell Transplantation Using Post-transplantation High-Dose Cyclophosphamide.
Solán L; Kwon M; Carbonell D; Dorado N; Balsalobre P; Serrano D; Chicano-Lavilla M; Anguita J; Gayoso J; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2019; 10():2338. PubMed ID: 31649665
[TBL] [Abstract][Full Text] [Related]
6. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
[TBL] [Abstract][Full Text] [Related]
7. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
8. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD.
Qayed M; Kapoor U; Gillespie S; Westbrook A; Aguayo-Hiraldo P; Ayuk FA; Aziz M; Baez J; Choe H; DeFilipp Z; Etra A; Grupp SA; Hexner E; Holler E; Hogan WJ; Kowalyk S; Merli P; Morales G; Nakamura R; Pulsipher MA; Schechter T; Shah J; Spyrou N; Srinagesh HK; Wölfl M; Yanik G; Young R; Kitko CL; Ferrara JLM; Levine JE
Transplant Cell Ther; 2024 Jun; 30(6):603.e1-603.e11. PubMed ID: 38548227
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.
Storb R; Gyurkocza B; Storer BE; Sorror ML; Blume K; Niederwieser D; Chauncey TR; Pulsipher MA; Petersen FB; Sahebi F; Agura ED; Hari P; Bruno B; McSweeney PA; Maris MB; Maziarz RT; Langston AA; Bethge W; Vindeløv L; Franke GN; Laport GG; Yeager AM; Hübel K; Deeg HJ; Georges GE; Flowers ME; Martin PJ; Mielcarek M; Woolfrey AE; Maloney DG; Sandmaier BM
J Clin Oncol; 2013 Apr; 31(12):1530-8. PubMed ID: 23478054
[TBL] [Abstract][Full Text] [Related]
10. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification.
Etra A; Gergoudis S; Morales G; Spyrou N; Shah J; Kowalyk S; Ayuk F; Baez J; Chanswangphuwana C; Chen YB; Choe H; DeFilipp Z; Gandhi I; Hexner E; Hogan WJ; Holler E; Kapoor U; Kitko CL; Kraus S; Lin JY; Al Malki M; Merli P; Pawarode A; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Van Hyfte G; Weber D; Wölfl M; Young R; Özbek U; Ferrara JLM; Levine JE
Blood Adv; 2022 Jun; 6(12):3707-3715. PubMed ID: 35443021
[TBL] [Abstract][Full Text] [Related]
11. Regenerating islet-derived protein 3-α is a prognostic biomarker for gastrointestinal chronic graft-versus-host disease.
DePriest BP; Li H; Bidgoli A; Onstad L; Couriel D; Lee SJ; Paczesny S
Blood Adv; 2022 May; 6(10):2981-2986. PubMed ID: 35030629
[TBL] [Abstract][Full Text] [Related]
12. Prognostic biomarkers for acute graft-versus-host disease risk after cyclophosphamide-fludarabine nonmyeloablative allotransplantation.
Nelson RP; Khawaja MR; Perkins SM; Elmore L; Mumaw CL; Orschell C; Paczesny S
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1861-4. PubMed ID: 25017764
[TBL] [Abstract][Full Text] [Related]
13. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
14. High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation.
Ponce DM; Hilden P; Mumaw C; Devlin SM; Lubin M; Giralt S; Goldberg JD; Hanash A; Hsu K; Jenq R; Perales MA; Sauter C; van den Brink MR; Young JW; Brentjens R; Kernan NA; Prockop SE; O'Reilly RJ; Scaradavou A; Paczesny S; Barker JN
Blood; 2015 Jan; 125(1):199-205. PubMed ID: 25377785
[TBL] [Abstract][Full Text] [Related]
15. Predictive Values of Early Suppression of Tumorigenicity 2 for Acute GVHD and Transplant-related Complications after Allogeneic Stem Cell Transplantation: Prospective Observational Study.
Matsumura A; Miyazaki T; Tachibana T; Ando T; Koyama M; Koyama S; Ishii Y; Takahashi H; Nakajima Y; Numata A; Yamamoto W; Motohashi K; Hagihara M; Matsumoto K; Fujisawa S; Nakajima H
Turk J Haematol; 2020 Feb; 37(1):20-29. PubMed ID: 31464120
[TBL] [Abstract][Full Text] [Related]
16. Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Aladağ Karakulak E; Demİroğlu H; Malkan UY; Akman U; Göker H; Büyükaşik Y
Turk J Med Sci; 2021 Feb; 51(1):355-358. PubMed ID: 32927932
[TBL] [Abstract][Full Text] [Related]
17. Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.
Russell JA; Duan Q; Chaudhry MA; Savoie ML; Balogh A; Turner AR; Larratt L; Storek J; Bahlis NJ; Brown CB; Quinlan D; Geddes M; Zacarias N; Daly A; Duggan P; Stewart DA
Biol Blood Marrow Transplant; 2008 Aug; 14(8):888-95. PubMed ID: 18640572
[TBL] [Abstract][Full Text] [Related]
18. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD.
Major-Monfried H; Renteria AS; Pawarode A; Reddy P; Ayuk F; Holler E; Efebera YA; Hogan WJ; Wölfl M; Qayed M; Hexner EO; Wudhikarn K; Ordemann R; Young R; Shah J; Hartwell MJ; Chaudhry MS; Aziz M; Etra A; Yanik GA; Kröger N; Weber D; Chen YB; Nakamura R; Rösler W; Kitko CL; Harris AC; Pulsipher M; Reshef R; Kowalyk S; Morales G; Torres I; Özbek U; Ferrara JLM; Levine JE
Blood; 2018 Jun; 131(25):2846-2855. PubMed ID: 29545329
[TBL] [Abstract][Full Text] [Related]
19. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant.
Aziz MD; Shah J; Kapoor U; Dimopoulos C; Anand S; Augustine A; Ayuk F; Chaudhry M; Chen YB; Choe HK; Etra A; Gergoudis S; Hartwell MJ; Hexner EO; Hogan WJ; Kitko CL; Kowalyk S; Kröger N; Merli P; Morales G; Nakamura R; Ordemann R; Pulsipher MA; Qayed M; Reshef R; Rösler W; Schechter T; Schreiner E; Srinagesh H; Wölfl M; Wudhikarn K; Yanik G; Young R; Özbek U; Ferrara JLM; Levine JE
Leukemia; 2020 Jul; 34(7):1898-1906. PubMed ID: 32020045
[TBL] [Abstract][Full Text] [Related]
20. Effect of pre-transplantation serum ferritin on outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation: A meta-analysis.
Yan Z; Chen X; Wang H; Chen Y; Chen L; Wu P; Wang W
Medicine (Baltimore); 2018 Jul; 97(27):e10310. PubMed ID: 29979374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
